Chart, page-3958

I'm hoping PAR do not enter into a trading halt just to release the results of a couple of secondary endpoints, it just seems overkill IMO. I've never seen a biopharma company place such a great deal of emphasis into their lower level secondary endpoints than PAR has. Other companies normally just released them to no fanfare at all, but i'm half expecting PAR to go into trading halt over the long weekend in typical PAR style. Anyway I'm hoping to still see some separation between the treatment and placebo groups as this will indicate not only possible durability but also disease-modifying properties.